[Media reports] Inventec Appliances and Good Future Upgraded cancer precision medicine technology won the National Innovation Award

The "IronMag®circulating tumor cells automated detection system" jointly developed by Inventec Appliances under Inventec and Good Future won the 17th National Innovation Award. Photo / provided by Inventec Appliances

Inventec Appliances, a subsidiary of Inventec Group (2356), cooperated with Good Future to jointly develop the "IronMag®circulating tumor cells automated detection system" for liquid slice detection technology in the field of cancer precision medicine. On December 1, it won the Biopharmaceutical and Precision Medicine category of the Enterprise Startup Group of the 17th National Innovation Award.

Liquid sectioning is a new strategy for cancer precision medicine. Detecting the presence of circulating tumor cells in the blood can provide the most direct evidence of cancer detection, "seeing is believing". Clinical detection is very important in all stages of cancer.

It is a pity that the existing detection platforms on the market are cumbersome, time-consuming, lack fully automated detection and other factors, which makes it impossible to carry out circulating tumor cells detection in clinical practice. This prevents cancer patients from getting more complete information on cancer changes. Breaking through this bottleneck is a top priority.

Inventec Appliances and Good Future adopted a different strategy from existing products on the market and used the "negative screening" mode to design the "IronMag®circulating tumor cells fully automatic detection system" product. By matching a dedicated reagent and consumable set, the system integrates circulating tumor cells's separation, immunofluorescence staining, cell image acquisition, AI-assisted image interpretation, manual review, automatic report output and other processes, greatly improving the accuracy and quality of circulating tumor cells detection.

Good Future pointed out that the "IronMag®circulating tumor cells automated detection system" is based on the negative screening mode that has been verified by hundreds of clinical cases of cancer patients. With the core design concept of all-in-one, it implements the fully automated circulating tumor cells detection mode of sample-in and data-out.

In addition to solving the bottleneck of most existing circulating tumor cells detection being unable to replace manual operations with fully automated mode, this system can stably separate trace amounts of circulating tumor cells from whole blood and has high detection specificity and sensitivity. It will also provide a new detection platform for the cancer precision medicine industry and the liquid slice application market.

Source----

Zhongshi News Network